Literature DB >> 18367531

Subdominant CD8 T-cell epitopes account for protection against cytomegalovirus independent of immunodomination.

Rafaela Holtappels1, Christian O Simon, Michael W Munks, Doris Thomas, Petra Deegen, Birgit Kühnapfel, Torsten Däubner, Simone F Emde, Jürgen Podlech, Natascha K A Grzimek, Silke A Oehrlein-Karpi, Ann B Hill, Matthias J Reddehase.   

Abstract

Cytomegalovirus (CMV) infection continues to be a complication in recipients of hematopoietic stem cell transplantation (HSCT). Preexisting donor immunity is recognized as a favorable prognostic factor for the reconstitution of protective antiviral immunity mediated primarily by CD8 T cells. Furthermore, adoptive transfer of CMV-specific memory CD8 T (CD8-T(M)) cells is a therapeutic option for preventing CMV disease in HSCT recipients. Given the different CMV infection histories of donor and recipient, a problem may arise from an antigenic mismatch between the CMV variant that has primed donor immunity and the CMV variant acquired by the recipient. Here, we have used the BALB/c mouse model of CMV infection in the immunocompromised host to evaluate the importance of donor-recipient CMV matching in immundominant epitopes (IDEs). For this, we generated the murine CMV (mCMV) recombinant virus mCMV-DeltaIDE, in which the two memory repertoire IDEs, the IE1-derived peptide 168-YPHFMPTNL-176 presented by the major histocompatibility complex class I (MHC-I) molecule L(d) and the m164-derived peptide 257-AGPPRYSRI-265 presented by the MHC-I molecule D(d), are both functionally deleted. Upon adoptive transfer, polyclonal donor CD8-T(M) cells primed by mCMV-DeltaIDE and the corresponding revertant virus mCMV-revDeltaIDE controlled infection of immunocompromised recipients with comparable efficacy and regardless of whether or not IDEs were presented in the recipients. Importantly, CD8-T(M) cells primed under conditions of immunodomination by IDEs protected recipients in which IDEs were absent. This shows that protection does not depend on compensatory expansion of non-IDE-specific CD8-T(M) cells liberated from immunodomination by the deletion of IDEs. We conclude that protection is, rather, based on the collective antiviral potential of non-IDEs independent of the presence or absence of IDE-mediated immunodomination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18367531      PMCID: PMC2395166          DOI: 10.1128/JVI.00155-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses.

Authors:  W Chen; L C Antón; J R Bennink; J W Yewdell
Journal:  Immunity       Date:  2000-01       Impact factor: 31.745

2.  Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).

Authors:  R Holtappels; J Podlech; N K Grzimek; D Thomas; M F Pahl-Seibert; M J Reddehase
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype.

Authors:  Rafaela Holtappels; Doris Thomas; Jürgen Podlech; Matthias J Reddehase
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 4.  Haematopoietic cell transplantation as immunotherapy.

Authors:  F R Appelbaum
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

5.  Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs.

Authors:  R Holtappels; M F Pahl-Seibert; D Thomas; M J Reddehase
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65).

Authors:  C S Morello; L D Cranmer; D H Spector
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication.

Authors:  Christopher S Morello; Ming Ye; Deborah H Spector
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

8.  Strong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challenge.

Authors:  Ming Ye; Christopher S Morello; Deborah H Spector
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

9.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.

Authors:  S R Riddell; K S Watanabe; J M Goodrich; C R Li; M E Agha; P D Greenberg
Journal:  Science       Date:  1992-07-10       Impact factor: 47.728

10.  Immunobiology of cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus.

Authors:  D Moskophidis; R M Zinkernagel
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

View more
  48 in total

1.  Enhancerless cytomegalovirus is capable of establishing a low-level maintenance infection in severely immunodeficient host tissues but fails in exponential growth.

Authors:  Jürgen Podlech; Rares Pintea; Kai A Kropp; Annette Fink; Niels A W Lemmermann; Katja C Erlach; Elena Isern; Ana Angulo; Peter Ghazal; Matthias J Reddehase
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

2.  The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4⁺ and CD8⁺ T-cell immunity.

Authors:  Jason P Twohig; Morgan Marsden; Simone M Cuff; John R Ferdinand; Awen M Gallimore; William V Perks; Aymen Al-Shamkhani; Ian R Humphreys; Eddie C Y Wang
Journal:  FASEB J       Date:  2012-05-16       Impact factor: 5.191

3.  Impact of regulated secretion on antiparasitic CD8 T cell responses.

Authors:  Harshita Satija Grover; H Hamlet Chu; Felice D Kelly; Soo Jung Yang; Michael L Reese; Nicolas Blanchard; Federico Gonzalez; Shiao Wei Chan; John C Boothroyd; Nilabh Shastri; Ellen A Robey
Journal:  Cell Rep       Date:  2014-05-22       Impact factor: 9.423

4.  Long-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant trans-Sialidase-Specific CD8+ T Cells.

Authors:  Charles S Rosenberg; Weibo Zhang; Juan M Bustamante; Rick L Tarleton
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

5.  The efficacy of antigen processing is critical for protection against cytomegalovirus disease in the presence of viral immune evasion proteins.

Authors:  Rafaela Holtappels; Doris Thomas; Matthias J Reddehase
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

6.  The immune evasion paradox: immunoevasins of murine cytomegalovirus enhance priming of CD8 T cells by preventing negative feedback regulation.

Authors:  Verena Böhm; Christian O Simon; Jürgen Podlech; Christof K Seckert; Dorothea Gendig; Petra Deegen; Dorothea Gillert-Marien; Niels A W Lemmermann; Rafaela Holtappels; Matthias J Reddehase
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

7.  Memory T cells persisting in the brain following MCMV infection induce long-term microglial activation via interferon-γ.

Authors:  Manohar B Mutnal; Shuxian Hu; Morgan R Little; James R Lokensgard
Journal:  J Neurovirol       Date:  2011-07-29       Impact factor: 2.643

8.  Competition for antigen at the level of the APC is a major determinant of immunodominance during memory inflation in murine cytomegalovirus infection.

Authors:  Lila A Farrington; Tameka A Smith; Finn Grey; Ann B Hill; Christopher M Snyder
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

9.  Immune evasion proteins of murine cytomegalovirus preferentially affect cell surface display of recently generated peptide presentation complexes.

Authors:  Niels A W Lemmermann; Kerstin Gergely; Verena Böhm; Petra Deegen; Torsten Däubner; Matthias J Reddehase
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  Cross-presentation of a spread-defective MCMV is sufficient to prime the majority of virus-specific CD8+ T cells.

Authors:  Christopher M Snyder; Jane E Allan; Elizabeth L Bonnett; Carmen M Doom; Ann B Hill
Journal:  PLoS One       Date:  2010-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.